natgillin/translations-raw huggingface dataset:
ABILIFY 5 mg tablets Indigo carmine aluminium lake (E 132)
ABILIFY 5 mg tablete Boja Indigo carmine aluminium lake (E 132) ABILIFY 10 mg tablete
The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively.
AUC dehidro-aripiprazola povisio se za 77 %, a Cmax za 43 %.
The overall completion rate was significantly higher for patients on oral aripiprazole (43 %) than for oral haloperidol (30 %).
Ukupna stopa dovršetka ispitivanja bila je značajno viša u skupini bolesnika koji su uzimali oralni aripiprazol (43 %) nego u onih na oralnom haloperidolu (30 %).
No dosage adjustment is required for patients with mild to moderate hepatic impairment.
Nije potrebno prilagođivati dozu u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
14 × 1 orodispersible tablets 28 × 1 orodispersible tablets 49 × 1 orodispersible tablets
14 × 1 raspadljiva tableta za usta 28 × 1 raspadljiva tableta za usta 49 × 1 raspadljiva tableta za usta
ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets aripiprazole
ABILIFY 5 mg tablete ABILIFY 10 mg tablete ABILIFY 15 mg tablete ABILIFY 30 mg tablete aripiprazol
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.
Populacijska farmakokinetička procjena oralnog aripiprazola nije otkrila nikakve dokaze klinički važnih učinaka pušenja na farmakokinetiku aripiprazola.
The efficacy of ABILIFY solution for injection in patients with agitation and disturbed behaviours has not been established related to conditions other than schizophrenia and manic episodes in Bipolar I Disorder.
Nije utvrđena djelotvornost ABILIFY otopine za injekciju u bolesnika s agitacijom i poremećenim ponašanjem uzrokovanim stanjima različitim od shizofrenije i maničnih epizoda u sklopu bipolarnog poremećaja tipa I.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).
U kliničkim ispitivanjima u odobrenim indikacijama i nakon stavljanja lijeka u promet, opaženo je i povećanje i smanjenje prolaktina u serumu uz aripiprazol u usporedbi s početim vrijednostima
The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial.
(najviše 26 tjedana) u ispitanika na aripiprazolu iznosilo je 3,2 kg, a u drugoj fazi ispitivanja (16 tjedana) zabilježeno je dodatno srednje povećanje od 2,2 kg u usporedbi s 0,6 kg u bolesnika koji su primali placebo.
There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Prijavljeni su agitacija, hipertonija, hipotonija, tremor,
A vial provides 9.75 mg in 1.3 mL.
Jedna bočica sadrži 9,75 mg u 1,3 ml.
Schizophrenia: in a long-term 52-week controlled trial, aripiprazole-treated patients had an overalllower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %).
Shizofrenija: u dugotrajnom kontroliranom ispitivanju u trajanju od 52 tjedna, bolesnici liječeni aripiprazolom imali su nižu ukupnu incidenciju (25,8 %) EPS-a uključujući parkinsonizam, akatiziju,
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores.
Adjuvantna terapija aripiprazolom se pokazala nadmoćnom u odnosu na placebo u sekundarnoj mjeri ishoda, rezultatima na ljestvici općeg kliničkog dojma za bipolarni poremećaj (engl.
Schizophrenia in adolescents aged 15 years and older: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals.
Shizofrenija u adolescenata u dobi od 15 i više godina: preporučena doza za ABILIFY je 10 mg/dan primijenjena jedanput dnevno neovisno o obroku.
Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).
Aripiprazol može izazvati reakcije preosjetljivosti, čije su značajke alergijski simptomi (vidjeti dio 4.8).
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
(uključujući plućnu emboliju i duboku vensku trombozu) hipertenzija sinkopa
If you stop taking ABILIFY
Ako prestanete uzimati ABILIFY
Package leaflet: Information for the user ABILIFY 1 mg/mL oral solution aripiprazole
Uputa o lijeku: Informacije za korisnika ABILIFY 1 mg/ml oralna otopina aripiprazol
Schizophrenia: the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day (i.e. 10 mL or 15 mL solution/day) with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Odrasli Shizofrenija: preporučena početna doza za ABILIFY je 10 mg/dan ili 15 mg/dan (tj. 10 ml ili 15 ml otopine/dan) uz dozu održavanja od 15 mg/dan koja se primjenjuje jedanput dnevno neovisno o obrocima.
ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
I te za prevenciju nove manične epizode u odraslih osoba s pretežno maničnim epizodama u kojih su prethodne manične epizode odgovorile na liječenje aripiprazolom (vidjeti dio 5.1).
In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, oral aripiprazole had significantly greater reduction in relapse rate, 34 % in oral aripiprazole group and 57 % in placebo.
U placebom kontroliranom ispitivanju u trajanju od 26 tjedana koje je uključilo stabilne odrasle bolesnike s kroničnom shizofrenijom, oralni aripiprazol je imao značajno veće smanjenje stope relapsa, 34 % u skupini koja je uzimala oralni aripiprazol u odnosu na 57 % u skupini koja je primala placebo.
The administration of lorazepam solution for injection had no effect on the pharmacokinetics of ABILIFY solution for injection when administered concomitantly.
Primjena lorazepam otopine za injekciju nije utjecala na farmakokinetiku ABILIFY otopine za injekciju prilikom istodobne primjene.
However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the intensity of sedation was greater with the combination as compared to that observed with aripiprazole alone.
Međutim, u ispitivanju jednokratne intramuskularne doze aripiprazola (od 15 mg) primijenjene istodobno s intramuskularnim lorazepamom (u dozi od 2 mg) u zdravih ispitanika, sedacija je bila jača uz kombinaciju tih lijekova nego kad se aripiprazol primijenio sam.
Manic episodes in Bipolar I Disorder in children and adolescents Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score ≥ 20 at baseline.
Aripiprazol se ispitivao u 30-tjednom placebom kontroliranom ispitivanju u kojem je sudjelovalo 296 djece i adolescenata (10 do 17 godina) koji su zadovoljavali DSM-IV kriterije (kriterije prema četvrtom izdanju Dijagnostičkog i statističkog priručnika za duševne poremećaje) za bipolarni poremećaj tipa
ABILIFY contains lactose
ABILIFY sadrži laktozu
Rectangular and blue, engraved with "A-007" and "5" on one side.
Pravokutna i plava s utisnutim oznakama "A-007" i "5" na jednoj strani.
Excipient with known effect 186.54 mg lactose (as monohydrate) per tablet
186,54 mg laktoze (u obliku laktoza hidrata) po tableti
How to take ABILIFY
Kako uzimati ABILIFY
• headache,
• glavobolja,
Neuroleptic Malignant Syndrome Grand mal convulsion Serotonin syndrome Speech disorder
Poremećaji živčanog sustava akatizija ekstrapiramidalni poremećaj tremor glavobolja sedacija somnolencija omaglica tardivna diskinezija distonija neuroleptički maligni sindrom konvulzije tipa grand mal serotoninski sindrom poremećaj govora
In the long-term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.
U dugotrajnoj fazi terapije održavanja u trajanju od 26 tjedana u sklopu jednog placebom kontroliranog ispitivanja, incidencija EPS-a bila je 18,2 % u bolesnika liječenih aripiprazolom i 15,7 % u bolesnika koji su primali placebo.
What you need to know before you take ABILIFY Do not take ABILIFY
Što morate znati prije nego primite ABILIFY
Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).
Zbog veće osjetljivosti ove populacije, potrebno je razmotriti primjenu niže početne doze kad to zahtijevaju klinički čimbenici
• not enough sodium in the blood,
• nedovoljna razina natrija u krvi,
In a long-term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients.
U dugotrajnom placebom kontroliranom ispitivanju u trajanju od 26 tjedana, incidencija EPS-a bila je 19 % u bolesnika liječenih aripiprazolom i 13,1 % u bolesnika koji su primali placebo.
Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
Jezgra tablete laktoza hidrat kukuruzni škrob celuloza, mikrokristalična hidroksipropilceluloza magnezijev stearat
In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26-week open-label extension trial.
koji su činili 74 % ukupne populacije uključene u ispitivanje, primijećeno je održanje učinka tijekom26-tjednog otvorenog produžetka ispitivanja.
• cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
• srčanih i krvožilnih bolesti, srčanih ili krvožilnih bolesti u obitelji, moždanog udara ili „mini“
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
Pušenje Procjenom populacijske farmakokinetike nije se otkrio dokaz klinički značajnih učinaka pušenja na farmakokinetiku aripiprazola.
ABILIFY orodispersible tablets are supplied in perforated unit dose blisters packed in cartons containing 14 × 1, 28 × 1, or 49 × 1 orodispersible tablets.
ABILIFY raspadljive tablete se isporučuju u blisterima djeljivima na jedinične doze pakiranima u kutije koje sadrže 14 × 1, 28 × 1 ili 49 × 1 raspadljive tablete.
Do not use this medicine after the expiry date which is stated on the bottle and on the carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake
These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings.
prekomjerno jedenje ili trošenje, abnormalno izražen seksualni poriv ili učestalo razmišljanje s povećanom količinom seksualnih misli ili osjećaja.
ABILIFY 10 mg orodispersible tablets ABILIFY 15 mg orodispersible tablets ABILIFY 30 mg orodispersible tablets
ABILIFY 10 mg raspadljive tablete za usta ABILIFY 15 mg raspadljive tablete za usta ABILIFY 30 mg raspadljive tablete za usta
• selective-serotonin-reuptake-inhibitors (SSRIs) (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety
kao i migrenu i bol • inhibitori ponovne pohrane serotonina (SSRI) (kao što su paroksetin i fluoksetin) koji se primjenjuju kod depresije, opsesivno-kompulzivnog poremećaja, panike i tjeskobe
Schizophrenia: the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Odrasli Shizofrenija: preporučena početna doza za ABILIFY je 10 mg/dan ili 15 mg/dan uz dozu održavanja od 15 mg/dan koja se primjenjuje jedanput dnevno neovisno o obrocima.
Agitation in schizophrenia and Bipolar I Disorder with ABILIFY solution for injection In two short- term (24-hour) placebo-controlled trials involving 554 schizophrenic adult patients presenting with agitation and disturbed behaviours, ABILIFYsolution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to haloperidol.
I uz ABILIFY otopinu za injekciju U dva kratkotrajna (24-satna), placebom kontrolirana ispitivanja u koja je bilo uključeno 554 odraslih bolesnika sa shizofrenijom i simptomima agitacije i poremećenog ponašanja, poboljšanje simptoma agitacije/ponašanja bilo je statistički značajno veće uz ABILIFY otopinu za injekciju u usporedbi s placebom i slično haloperidolu.
In one short-term (24-hour) placebo-controlled trial involving 291 patients with bipolar disorder presenting with agitation and disturbed behaviours, ABILIFY solution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to the reference arm lorazepam.
U jednom kratkotrajnom (24-satnom), placebom kontroliranom ispitivanju koje je uključilo 291 bolesnika s bipolarnim poremećajem i simptomima agitacije i poremećenog ponašanja, ABILIFY otopina za injekciju bila je povezana sa statistički značajno većim poboljšanjem navedenih simptoma u usporedbi s placebom te slično referentnoj skupini koja je primala lorazepam.
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged.
U kliničkom ispitivanju sa zdravim ispitanicima, jaki inhibitor CYP2D6 (kinidin) povećao je površinu ispod krivulje (AUC) aripiprazola za 107 %, dok je maksimalna koncentracija (Cmax) ostala neizmijenjena.
Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
Osim toga, aripiprazol i dehidro-aripiprazol in vitro nisu pokazali potencijal da mijenjaju metabolizam posredovan enzimom CYP1A2 pa stoga nije vjerojatno da će aripiprazol prouzročiti klinički važne interakcije s drugim lijekovima koji se metaboliziraju putem navedenih enzima.
Rectangular and pink, engraved with "A-008" and "10" on one side.
Pravokutna i ružičasta s utisnutim oznakama "A-008" i "10" na jednoj strani.
• difficulty in passing urine,
• poteškoće pri mokrenju,
Suicide attempt, suicidal ideation and completed suicide (see section 4.4)
kompulzivno kupovanje i kompulzivno prejedanje (vidjeti dio 4.4).
• high blood sugar,
• povišen šećer u krvi,
• agitation,
• uznemirenost,
ABILIFY tablets contain lactose.
ABILIFY tablete sadrže laktozu.
If you stop receiving ABILIFY
Ako prestanete primati ABILIFY
Schizophrenia with oral aripiprazole
Shizofrenija kod oralno primijenjenog aripiprazola
• decreased number of or difficulty making bowel movements,
• rjeđe ili otežano pražnjenje crijeva,
EU/1/04/276/033 (1 mg/mL, 50 mL per bottle) EU/1/04/276/034 (1 mg/mL, 150 mL per bottle) EU/1/04/276/035 (1 mg/mL, 480 mL per bottle)
EU/1/04/276/033 (1 mg/ml, boca od 50 ml) EU/1/04/276/034 (1 mg/ml, boca od 150 ml) EU/1/04/276/035 (1 mg/ml, boca od 480 ml)
• pain killers (such as tramadol and pethidine) used for pain relief
• lijekovi protiv bolova (kao što su tramadol i petidin) koji se primjenjuju za ublažavanje boli
It has been proposed that aripiprazole's efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
I jest da je ono posredovano kombinacijom djelomičnog agonizma s dopaminskim D2 i serotoninskim 5-HT1A
ABILIFY 7.5 mg/mL solution for injection
ABILIFY 7,5 mg/ml otopina za injekciju
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
10 do 17 godina bila je slična onoj u odraslih bolesnika nakon korekcije za razliku u tjelesnoj težini.
ABILIFY contains fructose and sucrose
ABILIFY sadrži fruktozu i saharozu
ABILIFY 5 mg tablets are rectangular and blue, marked with ‘A-007' and ‘5' on one side.
ABILIFY 5 mg tablete su pravokutne i plave, s oznakama ‘A-007' i ‘5' na jednoj strani.
ABILIFY 1 mg/mL oral solution aripiprazole
ABILIFY 1 mg/ml oralna otopina aripiprazol
Orodispersible tablets
Raspadljive tablete za usta
In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
U šestotjednom, placebom kontroliranom ispitivanju u koje su bila uključena 302 adolescentna bolesnika sa shizofrenijom (u dobi od 13 do 17 godina) i prisutnim pozitivnim ili negativnim simptomima, aripiprazol je bio povezan sa statistički značajno većim poboljšanjem psihotičnih simptoma u usporedbi s placebom.
In clinical studies, oral doses of 10 mg/day to 30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
Potencijal aripiprazola da utječe na druge lijekove U kliničkim ispitivanjima, doze aripiprazola od 10 mg/dan do 30 mg/dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ni CYP3A4 (dekstrometorfan).
Each mL contains 1 mg of aripiprazole.
Jedan ml sadrži 1 mg aripiprazola.
In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning.
S obzirom na veličinu terapijskog učinka u odnosu na veliki učinak placeba i nejasne učinke u pogledu psihosocijalnog funkcioniranja, u ova dva kratkotrajna ispitivanja nije ustanovljena klinička važnost pronađene djelotvornosti.
ABILIFY 15 mg orodispersible tablets: This medicine contains 3 mg aspartame in each tablet.
ABILIFY 15 mg raspadljive tablete za usta: Ovaj lijek sadrži 3 mg aspartama u jednoj tableti.
ABILIFY 7.5 mg/mL solution for injection aripiprazole
ABILIFY 7,5 mg/ml otopina za injekciju aripiprazol
EU/1/04/276/033 - 50 mL bottle EU/1/04/276/034 - 150 mL bottle EU/1/04/276/035 - 480 mL bottle
EU/1/04/276/033 - boca od 50 ml EU/1/04/276/034 - boca od 150 ml EU/1/04/276/035 - boca od 480 ml
• weight loss,
• smanjenje tjelesne težine,
OUTER CARTON AND BOTTLE LABEL
NALJEPNICA BOČICE
Solution for injection Clear, colourless, aqueous solution.
Otopina za injekciju Bistra, bezbojna, vodena otopina
ABILIFY 30 mg orodispersible tablets: This medicine contains 6 mg aspartame in each tablet.
ABILIFY 30 mg raspadljive tablete za usta: Ovaj lijek sadrži 6 mg aspartama u jednoj tableti.
Each mL contains 7.5 mg of aripiprazole.
Jedan ml sadrži 7,5 mg aripiprazola.
Impulse control disorders may result in harm to the patient and others if not recognised.
Ako se ne prepoznaju, poremećaji kontrole nagona mogu naškoditi kako bolesniku,
Renal impairment No dosage adjustment is required in patients with renal impairment.
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije bubrega.
Tics associated with Tourette's disorder in paediatric patients (see section 4.2) The efficacy of aripiprazole was studied in paediatric subjects with Tourette's disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo-controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg.
Djelotvornost aripiprazola bila je ispitana u pedijatrijskih ispitanika s Touretteovim sindromom (aripiprazol: n = 99, placebo: n = 44) u randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju u trajanju od 8 tjedana u kojem su terapijske skupine primale fiksne doze na temelju tjelesne težine u rasponu od 5 mg na dan do 20 mg na dan, uz početnu dozu od 2 mg.
Aluminium perforated unit dose blisters in cartons of 14 × 1, 28 × 1, 49 × 1 tablets.
Aluminijski perforirani blisteri djeljivi na jedinične doze u kutijama s 14 × 1, 28 × 1, 49 × 1 tabletom.
In the adolescent (13 to 17 years) schizophrenia population with aripiprazole exposure of 5 mg to 30 mg up to 72 months, incidence of low serum prolactin levels in females (< 3 ng/mL) and males (< 2 ng/mL) was 25.6 % and 45.0 %, respectively.
U populaciji adolescenata (u dobi od 13 do 17 godina) sa shizofrenijom koji su bili izloženi aripiprazolu u dozi od 5 mg do 30 mg do 72 mjeseca, incidencija niskih razina prolaktina u serumu u djevojaka (< 3 ng/ml) iznosila je 25,6 %, a u mladića (< 2 ng/ml) 45,0 %.
• The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropylcellulose and magnesium stearate.
• Drugi sastojci su laktoza hidrat, kukuruzni škrob, mikrokristalična celuloza,
In clinical trials oral aripiprazole has not been shown to induce clinically relevant weight gain.
U kliničkim se ispitivanjima nije pokazalo da oralni aripiprazol inducira klinički značajno povećanje tjelesne težine.
ABILIFY 15 mg orodispersible tablets 15 mg: Round and yellow, marked with "A" over "641" on one side and "15" on the other.
ABILIFY 15 mg raspadljive tablete za usta 15 mg: Okrugla i žuta s oznakom "A" iznad "641" na jednoj strani i "15" na drugoj.
once a day.
30 mg jedanput dnevno.
ABILIFY 10 mg orodispersible tablets: This medicine contains 2 mg aspartame in each tablet.
ABILIFY 10 mg raspadljive tablete za usta: Ovaj lijek sadrži 2 mg aspartama u jednoj tableti.
ABILIFY solution for injection contains sodium.
Natrij ABILIFY otopina za injekciju sadrži natrij.
When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1).
Po potrebi, doza se može dalje povećavati u koracima od po 5 mg, s time da se ne smije prekoračiti maksimalna dnevna doza od
ABILIFY orodispersible tablets contain aspartame.
Aspartam ABILIFY raspadljive tablete za usta sadrže aspartam.
Each carton contains one single-use type I glass vial with a rubber butyl stopper and a "tear-off" aluminium seal.
I za jednokratnu uporabu, s čepom od butilne gume i aluminijskim prstenom.
Blood glucose fluctuation Creatine phosphokinase increased
Nepoznato fosfataze produljen QT interval povišena glukoza u krvi povišen glikirani hemoglobin fluktuacija glukoze u krvi povišena vrijednost kreatin fosfokinaze
How to store ABILIFY
Kako primjenjivati ABILIFY
In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, oral aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
U tri kratkotrajna (4 do 6 tjedana), placebom kontrolirana ispitivanja koja su uključila 1228 odraslih bolesnika s pozitivnim ili negativnim simptomima shizofrenije, oralni aripiprazol je bio povezan sa statistički značajno većim poboljšanjima psihotičnih simptoma u usporedbi s placebom.
In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
U tri kratkotrajna (4 do 6 tjedana), placebom kontrolirana ispitivanja koja su uključila 1228 odraslih bolesnika s pozitivnim ili negativnim simptomima shizofrenije, aripiprazol je bio povezan sa statistički značajno većim poboljšanjima psihotičnih simptoma u usporedbi s placebom.